29477-83-6
基本信息
水仙環(huán)素對照品
水仙環(huán)素標(biāo)準(zhǔn)品
水仙環(huán)素?, 99.9%
NSC 266535
Narciclasin
BRN 1087400
Lycorcidinol
narciclasine
Lycoricidin-A
Narciclasine, 99.9%
(13β)-1,19-Didehydro-2α,3β,4β,7-tetrahydroxy-11,12-dinor-5,19-secocrinan-6-one
3,4,4a,5-Tetrahydro-2,3,4,7-tetrahydroxy-(1,3)dioxolo(4,5-j)phenanthridin-6(2H)-one
物理化學(xué)性質(zhì)
常見問題列表
ROCK
|
Narciclasine activates Rho and stress fibers in glioblastoma multiforme cells. The mean IC 50 of ~50 nM calculated on the 6 human glioblastoma multiforme (U373, Hs683, GL19, GL5, GL16, GL17), The mean IC 50 value of 47 nM for Narciclasine across a panel of 60 cancer cell lines. Bioassay-guided fractionation of the A. belladonna extract resulted in the identification of lycorine as the bio-active compound. The IC 50 measured for radicle growth inhibition is 0.1 μM for Narciclasine.
The i.v. regimen of Narciclasine at 1 mg/kg significantly (P=0.02) increases the survival of GL19 glioblastoma multiforme-bearing mice. Narciclasine when given orally at the same dose five times a week for 5 consecutive weeks also significantly increases animal survival in this model (P=0.008). Oral treatment with Narciclasine at 1 mg/kg significantly increases the survival (P=0.004) of Hs683 glioblastoma multiforme-bearing mice. Increasing the number of doses administered per week does not increase the survival of these Hs683 glioblastoma multiforme-bearing mice. Narciclasine appears to show similar increased survival in these models to temozolomide but at appreciable lower doses and following both oral and i.v. administration.